CRISPR 技术在细胞免疫治疗中的应用。
Applications of CRISPR technology in cellular immunotherapy.
机构信息
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
System Biology Institute, Yale University, West Haven, Connecticut, USA.
出版信息
Immunol Rev. 2023 Nov;320(1):199-216. doi: 10.1111/imr.13241. Epub 2023 Jul 14.
Abstract
CRISPR technology has transformed multiple fields, including cancer and immunology. CRISPR-based gene editing and screening empowers direct genomic manipulation of immune cells, opening doors to unbiased functional genetic screens. These screens aid in the discovery of novel factors that regulate and reprogram immune responses, offering novel drug targets. The engineering of immune cells using CRISPR has sparked a transformation in the cellular immunotherapy field, resulting in a multitude of ongoing clinical trials. In this review, we discuss the development and applications of CRISPR and related gene editing technologies in immune cells, focusing on functional genomics screening, gene editing-based cell therapies, as well as future directions in this rapidly advancing field.
摘要
CRISPR 技术已经改变了多个领域，包括癌症和免疫学。基于 CRISPR 的基因编辑和筛选使免疫细胞的直接基因组操作成为可能，为无偏功能遗传筛选开辟了道路。这些筛选有助于发现调节和重编程免疫反应的新因素，提供新的药物靶点。使用 CRISPR 工程化免疫细胞已经引发了细胞免疫治疗领域的变革，导致了大量正在进行的临床试验。在这篇综述中，我们讨论了 CRISPR 及相关基因编辑技术在免疫细胞中的发展和应用，重点介绍了功能基因组筛选、基于基因编辑的细胞疗法，以及这个快速发展领域的未来方向。
相似文献
1
Applications of CRISPR technology in cellular immunotherapy.CRISPR 技术在细胞免疫治疗中的应用。
Immunol Rev. 2023 Nov;320(1):199-216. doi: 10.1111/imr.13241. Epub 2023 Jul 14.
2
Genome-scale CRISPR-Cas9 screening in stem cells: theories, applications and challenges.基于干细胞的全基因组 CRISPR-Cas9 筛选：理论、应用和挑战。
Stem Cell Res Ther. 2024 Jul 19;15(1):218. doi: 10.1186/s13287-024-03831-z.
3
CRISPR/Cas genome editing in soybean: challenges and new insights to overcome existing bottlenecks.大豆中的CRISPR/Cas基因组编辑：克服现有瓶颈的挑战与新见解
J Adv Res. 2024 Aug 18. doi: 10.1016/j.jare.2024.08.024.
4
Unlocking the potential of CRISPR-Cas9 for cystic fibrosis: A systematic literature review.挖掘CRISPR-Cas9治疗囊性纤维化的潜力：一项系统文献综述
Gene. 2025 Mar 20;942:149257. doi: 10.1016/j.gene.2025.149257. Epub 2025 Jan 18.
5
Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.细胞穿透肽与 CRISPR-Cas9：用于人类遗传疾病治疗的联合策略。
Hum Gene Ther. 2024 Oct;35(19-20):781-797. doi: 10.1089/hum.2024.020.
6
Extracellular Vesicle-Mediated Delivery of Genetic Material for Transformation and CRISPR/Cas9-based Gene Editing in .用于转化和基于CRISPR/Cas9的基因编辑的细胞外囊泡介导的遗传物质递送
bioRxiv. 2025 Jun 17:2025.06.17.660080. doi: 10.1101/2025.06.17.660080.
7
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach.表观遗传编辑与表观遗传药物：一种同时靶向KDM4的联合策略，作为一种新型抗癌方法。
Clin Epigenetics. 2025 Jun 19;17(1):105. doi: 10.1186/s13148-025-01913-0.
8
Transferable approaches to CRISPR-Cas9 induced genome editing in non-model insects: a brief guide.非模式昆虫中CRISPR-Cas9介导的基因组编辑的可转移方法：简要指南
Front Zool. 2025 Jul 7;22(1):13. doi: 10.1186/s12983-025-00566-2.
9
CRISPR/Cas9-mediated genome editing in Ganoderma lucidum: recent advances and biotechnological opportunities.CRISPR/Cas9介导的灵芝基因组编辑：最新进展与生物技术机遇
World J Microbiol Biotechnol. 2025 Jun 25;41(7):223. doi: 10.1007/s11274-025-04458-9.
10
Genome Editing in the Yellow Fever Mosquito Aedes aegypti using CRISPR-Cas9.利用CRISPR-Cas9对黄热病蚊子埃及伊蚊进行基因组编辑。
J Vis Exp. 2025 Mar 21(217). doi: 10.3791/67732.
引用本文的文献
1
Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.实体瘤的工程化免疫细胞疗法：药理学进展、临床结果及未来方向。
Front Pharmacol. 2025 Jun 12;16:1614325. doi: 10.3389/fphar.2025.1614325. eCollection 2025.
2
Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology.揭开基因组学的未来：CRISPR、单细胞组学及其在癌症和免疫学中的应用。
Front Genome Ed. 2025 Apr 11;7:1565387. doi: 10.3389/fgeed.2025.1565387. eCollection 2025.
3
Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies.变革性免疫疗法：揭开基于嵌合抗原受体T细胞（CAR-T）基因疗法的新视野、应对挑战并探索治疗前沿
Immunotargets Ther. 2024 Aug 27;13:413-433. doi: 10.2147/ITT.S474659. eCollection 2024.
4
High-throughput CRISPR technology: a novel horizon for solid organ transplantation.高通量 CRISPR 技术：实体器官移植的新视野。
Front Immunol. 2024 Jan 4;14:1295523. doi: 10.3389/fimmu.2023.1295523. eCollection 2023.
5
Applications of CRISPR screening to lung cancer treatment.CRISPR筛选在肺癌治疗中的应用。
Front Cell Dev Biol. 2023 Dec 15;11:1295555. doi: 10.3389/fcell.2023.1295555. eCollection 2023.
6
Golden age of immunoengineering.免疫工程的黄金时代。
Immunol Rev. 2023 Nov;320(1):4-9. doi: 10.1111/imr.13283. Epub 2023 Oct 23.
本文引用的文献
1
CTLA-4 tail fusion enhances CAR-T antitumor immunity.CTLA-4 尾融合增强 CAR-T 抗肿瘤免疫。
Nat Immunol. 2023 Sep;24(9):1499-1510. doi: 10.1038/s41590-023-01571-5. Epub 2023 Jul 27.
2
High-content CRISPR screening.高内涵CRISPR筛选
Nat Rev Methods Primers. 2022;2(1). doi: 10.1038/s43586-022-00098-7. Epub 2022 Feb 10.
3
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes.肽介导的 CRISPR 酶递送来高效编辑原代人淋巴细胞。
Nat Biomed Eng. 2023 May;7(5):647-660. doi: 10.1038/s41551-023-01032-2. Epub 2023 Apr 25.
4
Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus.通过整合酶缺陷型慢病毒的基因敲入实现大转基因的稳定表达。
Nat Biomed Eng. 2023 May;7(5):661-671. doi: 10.1038/s41551-023-01037-x. Epub 2023 May 1.
5
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.将不同的 CRISPR 核酸酶用于同时进行基因敲入和碱基编辑可防止多重编辑的 CAR T 细胞发生易位。
Genome Biol. 2023 Apr 24;24(1):89. doi: 10.1186/s13059-023-02928-7.
6
Efficient engineering of human and mouse primary cells using peptide-assisted genome editing.使用肽辅助基因组编辑技术高效工程化人类和小鼠原代细胞。
Nat Biotechnol. 2024 Feb;42(2):305-315. doi: 10.1038/s41587-023-01756-1. Epub 2023 Apr 24.
7
Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.腺嘌呤碱基编辑恢复 CD3δ 重症联合免疫缺陷患者的人 T 细胞生成
Cell. 2023 Mar 30;186(7):1398-1416.e23. doi: 10.1016/j.cell.2023.02.027. Epub 2023 Mar 20.
8
Neoantigen-targeted CD8 T cell responses with PD-1 blockade therapy.PD-1 阻断治疗的靶向新抗原的 CD8 T 细胞反应。
Nature. 2023 Mar;615(7953):697-704. doi: 10.1038/s41586-023-05787-1. Epub 2023 Mar 8.
9
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy.删除 SNX9 可减轻 CD8 T 细胞衰竭，从而有效进行细胞癌症免疫治疗。
Nat Commun. 2023 Feb 2;14(1):86. doi: 10.1038/s41467-022-35583-w.
10
Massively parallel knock-in engineering of human T cells.大规模平行基因敲入人 T 细胞工程。
Nat Biotechnol. 2023 Sep;41(9):1239-1255. doi: 10.1038/s41587-022-01639-x. Epub 2023 Jan 26.
Zotero 插件